Transforming the
basic biomedical knowledge
into economic and social value

The Spanish Biotechnological Sector Association (ASEBIO) had renewed several key positions including the Presidency, Vice presidency and nine of its Directive Board members.
As Vice presidents, José María Fernández Sousa-Faro, Zeltia´s Groups vice president and Antonio Vallespir, Abengoa Bioenergy´s CEO, will work with the President, Regina Revilla in her 2-year mandate.
The recently named president will work to accomplish better R+D fiscal incentives, introduce the biotechnology as a political government priority, increase ASEBIO´s associative base and promote a better use and industrial biotechnology Development.
Also, ASEBIO´s General Assembly had renewed nine Directive Board committee positions, now held by: Oryzon (Carlos Buesa); Grifols Engineering (Esperanza Guisado); AB-Biotics (Miquel Angel Bonachera); Ingenasa (Carmen Vela); Neuron Biopharma (Javier Velasco); Digna Biotech (Pablo Ortiz); Janus Development (María Isabel Berges); Esteve (Eduard Valentí) and GP Pharm (Alberto Bueno). The rest of the committee positions are held by: Amgen (Jordi Martí); Biópolis (Daniel Ramón); Farmasierra (Tomás Olleros); Cellerix (Eduardo Bravo); Genetrix (Pilar de la Huerta); Genzyme (Fernando Royo); Vivia Biotech (Andrés Ballesteros) and Merck (Santiago Almazán).